Genetics of lipoprotein abnormalities associated with coronary heart disease susceptibility

Annual Review of Genetics

Volumn 34, Issue , 2000, Pages 233-254

  Breslow, J L ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Apo E; Coronary heart disease; Familial combined hyperlipidemia; Genetics; HDL; LDL; Lipoprotein(a); Lipoproteins; Triglycerides

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

DYSLIPOPROTEINEMIA; FAMILIAL DISEASE; GENE CONTROL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW;

EID: 0034507636     PISSN: 00664197     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genet.34.1.233     Document Type: Review

References (122)

1. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles
2. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease
3. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice
4. DNA polymorphisms of the apolipoprotein AI/CIII/AIV gene cluster influence plasma cholesterol and triglyceride levels in the Mayans of the Yucatan Peninsula, Mexico
5. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia
6. Linkage of a candidate gene locus to familial combined hyperlipidemia:lecithin:cholesterol acyltransferase on 16q
7. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11
8. Triacylglycerol and coronary heart disease
9. Low-density lipoprotein subclass patterns and risk of myocardial infarction
10. Familial combined hyperlipidemia and abnormal lipoprotein lipase
11. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
12. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations
13. Human HDL cholesterol levels are determined by apoA-I fractional catabolic rate, which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution
14. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
15. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins
16. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells
17. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: Evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci
18. Mapping a gene for combined hyperlipidaemia in a mutant mouse strain
19. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: Correlation with changes in plasma triglyceride levels
20. A new locus for autosomal recessive hypercholesterolemia maps to human chromosome 15q25-q26
21. Hepatic lipase: New insights from genetic and metabolic studies
22. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels
23. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: Effects on LDL-cholesterol and apolipoproteins B and C-III
24. Complex genetic contribution of the Apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia. Identification of different susceptibility haplotypes
25. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms
26. Mechanism of HDL mediated anti-atherogenesis: The human apolipoprotein A-I transgene inhibits foam cell formation in apolipoprotein E-deficient mice at a stage following monocyte adherence to endothelium
27. Apolipoprotein E polymorphism and atherosclerosis
28. Metabolic and genetic determinants of HDL metabolism and hepatic lipase activity in normolipidemic females
29. Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects
30. Role of apolipoprotein E in the lipolytic conversion of beta-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia
31. Mutations in the apolipoprotein (apo) B-100 receptor-binding region: Detection of apo B-100 (Arg3500→Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405→Gln) diminishes receptor-mediated uptake of LDL
32. Common variation in the lipoprotein lipase gene: Effects on plasma lipids and risk of atherosclerosis
33. Relationship of the phenotypic expression of the A-IMilano apoprotein with plasma lipid and lipoprotein patterns
34. Regulation of plasma HDL cholesterol and subfraction distribution by genetic and environmental factors. Associations between the TaqI B RFLP in the CETP gene and smoking and obesity
35. Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia
36. Familial lipoprotein disorders in patients with premature coronary artery disease
37. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia
38. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
39. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology
40. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high density lipoprotein cholesterol
41. Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred
42. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
43. Familial defective apolipoprotein B-100
44. DNA polymorphisms in and around the Apo-A1-CIII genes and genetic hyperlipidemias
45. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III
46. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity
47. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group
48. Lipoprotein(a): Intrigues and insights
49. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
50. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol
51. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice
52. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients
53. Apolipoprotein multigene family: Tandem organization of human apolipoprotein AI, CIII, and AIV genes
54. Linkage of human apolipoproteins A-I and C-III genes
55. Mortality rates and risk factors for coronary disease in black as compared with white men and women
56. A cholesterol-lowering gene maps to chromosome 13q
57. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels
58. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein
59. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: Confounding effect of linkage disequilibrium
60. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway
61. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia
62. Familial hypobetalipoproteinemia
63. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins
64. Genetics of atherosclerosis
65. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia
66. Lack of association of the apolipoprotein A-I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects
67. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux
68. The Apo(a) gene is the major determinant of variation in plasma Lp(a) levels in African Americans
69. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study
70. Hepatic lipase gene polymorphisms influence plasma HDL levels. Results from Finnish EARS participants. European atherosclerosis research study
71. The LPL gene in individuals with familial combined hyperlipidemia and decreased LPL activity
72. Three polymorphisms associated with low hepatic lipase activity are common in African Americans
73. Molecular basis of congenital 1p(a) deficiency: A frequent apo(a) 'null' mutation in caucasians
74. Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23
75. No evidence of linkage between familial combined hyperlipidemia and genes encoding lipolytic enzymes in Finnish families
76. Genomewide scan for familial combined hyperlipidemia genes in Finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels
77. Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans
78. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
79. Phenotype expression in familial combined hyperlipidemia
80. Familial ligand-defective apolipoprotein B-100: Simultaneous detection of the ARG3500→GLN and ARG3531→CYS mutations in a French population
81. Banting lecture 1988. Role of insulin resistance in human disease
82. DNA polymorphism adjacent to human apoprotein A-1 gene: Relation to hypertriglyceridaemia
83. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred
84. Atherosclerosis - An inflammatory disease
85. Clinical outcomes in statin treatment trials: A meta-analysis
86. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
87. Lipoprotein (a). Heterogeneity and biological relevance
88. The hypobetalipoproteinemias
89. Hepatic lipase (LIPC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations
90. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates
91. Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins
92. Haplotypes of the ApoA-I/C-III/A-IV gene cluster and familial combined hyperlipidemia
93. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT study invsestigators
94. A missense mutation in the cholesteryl ester transfer protein gene with possible dominant effects on plasma high density lipoproteins
95. Strong association of a single nucleotide substitution in the 3′-untranslated region of the apolipoprotein-CIII gene with common hypertriglyceridemia in Arabs
96. Rare and common mutations in hyperlipidemia and atherosclerosis. With special reference to familial defective apolipoprotein B-100
97. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis
98. Genetic architecture and evolution of the lipoprotein(a) trait
99. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32
100. Hepatic lipase activity is lower in African American men than in white American men: Effects of 5′ flanking polymorphism in the hepatic lipase gene (LIPC)
101. Apolipoprotein A-I variants. Naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I
102. Structural analysis of human apolipoprotein A-I variants. Amino acid substitutions are nonrandomly distributed throughout the apolipoprotein A-I primary structure
103. Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations
104. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E
105. Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112
106. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI-CIII-AIV gene complex
107. Prediction of coronary heart disease using risk factor categories
108. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis
109. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease
110. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis
111. Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24
112. Association between genetic variation at the APO AI-CIII-AIV gene cluster and familial combined hyperlipidaemia
113. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol
114. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and post-translational modification
115. Human apolipoprotein E isoprotein subclasses are genetically determined
116. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population